Search - tctmd.com

Displaying 301 - 320 of 615

Sort: Relevancy | Date

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

OMT Boosts Survival in Revascularized Patients at 10 Years

Michael O'Riordan

June 29, 2021

News Daily News

Less Cancer Among HF Patients Taking Statins, Registry Shows

Michael O'Riordan

June 23, 2021

News Daily News

Statins Not Linked to Dementia or Memory Changes: ASPREE

Michael O'Riordan

June 21, 2021

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

News Daily News

First PCIs Preceded by Many Modifiable Risk Factors: Registry Data

L.A. McKeown

June 16, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Shelley Wood

May 16, 2021

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

Todd Neale

May 14, 2021

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

News Conference News ACC 2021

Prediabetes Linked to Higher MACE Risk

Todd Neale

May 10, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Conference News SCAI 2021

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

Michael O'Riordan

April 28, 2021

News Daily News

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Michael O'Riordan

April 21, 2021

News Daily News

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Michael O'Riordan

April 02, 2021

News Daily News

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

Caitlin E. Cox

March 24, 2021

Advertisement

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

OMT Boosts Survival in Revascularized Patients at 10 Years

Less Cancer Among HF Patients Taking Statins, Registry Shows

Statins Not Linked to Dementia or Memory Changes: ASPREE

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

First PCIs Preceded by Many Modifiable Risk Factors: Registry Data

June 2021 News Roundup

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Dapagliflozin No Help, but No Harm, in Hospitalized COVID-19 Patients

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Diabetes Duration and Meds Don’t Impact Ticagrelor Effects in THEMIS

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Prediabetes Linked to Higher MACE Risk

FDA Approves Dapagliflozin for CKD Patients

In African-American Patients, Nontraditional Risk Factors Track With Early CAD

In Female Veterans With Early ASCVD, Secondary Prevention Falls Short

Continue ACE Inhibitors/ARBs in COVID-19, New Study Confirms

Pills for Erectile Dysfunction Linked to Fewer CVD Deaths

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content